118 related articles for article (PubMed ID: 36745485)
1. Mass balance study of [
Ge X; Ma S; Yan S; Wu Y; Chen C; Tang C; Zhan Y; Bian YC; Shen K; Feng S; Gao X; Zhong D; Zhang H; Miao LY; Diao XX
Xenobiotica; 2023 Feb; 53(2):69-83. PubMed ID: 36745485
[TBL] [Abstract][Full Text] [Related]
2. Absorption, metabolism, and excretion of [
Yu J; Zhang H; Zhang Y; Zhan Y; Ma S; Hu T; Zhang N; Lou Y; Bao H; Xu Z; Zhong D; Miao L; Diao X
Xenobiotica; 2022 Mar; 52(3):254-264. PubMed ID: 35373704
[TBL] [Abstract][Full Text] [Related]
3. Mass balance study of [14C] rabeprazole following oral administration in healthy subjects.
Setoyama T; Drijfhout WJ; van de Merbel NC; Humphries TJ; Hasegawa J
Int J Clin Pharmacol Ther; 2006 Nov; 44(11):557-65. PubMed ID: 17176622
[TBL] [Abstract][Full Text] [Related]
4. Absorption, metabolism, excretion, and safety of [
Zhou C; Xie L; Liu W; Zhang L; Zhou S; Wang L; Chen J; Li H; Zhao Y; Zhu B; Ding S; Zhang C; Shao F
Ann Transl Med; 2021 May; 9(10):867. PubMed ID: 34164501
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics, mass balance, and metabolism of [
Zheng YD; Zhang H; Zhan Y; Bian YC; Ma S; Gan HX; Lai XJ; Liu YQ; Gong YC; Liu XF; Sun HB; Li YG; Zhong DF; Miao LY; Diao XX
Acta Pharmacol Sin; 2021 Sep; 42(9):1535-1546. PubMed ID: 33244163
[TBL] [Abstract][Full Text] [Related]
6. Mass balance, metabolic disposition, and pharmacokinetics of a novel selective inhibitor of PI3Kδ [
Guo F; Liu B; Li X; Wang H; Zhu X; Su Y; He C; Zhu M; Ding J; Xu Y; Zhao X; Wang Y; Shan R; Zhu J; Xie J; Ge Q; Fan L; Ding Y; Xie Y; Zhang C; Li H; Wang H; Zhou H
Cancer Chemother Pharmacol; 2023 Feb; 91(2):143-156. PubMed ID: 36572783
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Study to Evaluate the Safety and Pharmacokinetics of SHR0302 Base Ointment in Healthy Adult Volunteers.
Li B; Li N; Goh AH; Cao H; Irwin MW; Tong X; Wang J; Wu X; Zhang J; Pu D
Skin Pharmacol Physiol; 2023; 36(2):76-86. PubMed ID: 36580897
[TBL] [Abstract][Full Text] [Related]
8. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Zhao Y; Zhang L; Ding Y; Tao X; Ji C; Dong X; Lu J; Wu L; Wang R; Lu Q; Goh AH; Liu R; Zhang Z; Zhang J
Am J Clin Dermatol; 2021 Nov; 22(6):877-889. PubMed ID: 34374027
[TBL] [Abstract][Full Text] [Related]
10. JAK1-STAT3 blockade by JAK inhibitor SHR0302 attenuates inflammatory responses of adjuvant-induced arthritis rats and decreases Th17 and total B cells.
Wu H; Yan S; Chen J; Luo X; Li P; Jia X; Dai X; Wang C; Huang Q; Liu L; Zhang Y; Zhou A; Chang Y; Zhang L; Wei W
Joint Bone Spine; 2016 Oct; 83(5):525-32. PubMed ID: 26832189
[TBL] [Abstract][Full Text] [Related]
11. Mass balance, metabolic disposition, and pharmacokinetics of [
Zhou S; Liu W; Zhou C; Zhang L; Xie L; Xu Z; Wang L; Zhao Y; Guo L; Chen J; Ding L; Mao L; Tao Y; Zhang C; Ding S; Shao F
Cancer Chemother Pharmacol; 2020 Dec; 86(6):719-730. PubMed ID: 33044566
[TBL] [Abstract][Full Text] [Related]
12. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.
Shilling AD; Nedza FM; Emm T; Diamond S; McKeever E; Punwani N; Williams W; Arvanitis A; Galya LG; Li M; Shepard S; Rodgers J; Yue TY; Yeleswaram S
Drug Metab Dispos; 2010 Nov; 38(11):2023-31. PubMed ID: 20699411
[TBL] [Abstract][Full Text] [Related]
13. [The anti-proliferative and anti-inflammatory mechanisms of JAK1 inhibitor SHR0302 versus Ruxolitinib in SET2 cell line and primary cells].
Yang AY; Liu JQ; Cai YN; Fang MY; Yang L; Chen M; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1003-1007. PubMed ID: 32023730
[No Abstract] [Full Text] [Related]
14. Excretion balance and pharmacokinetics following a single oral dose of [
Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
[TBL] [Abstract][Full Text] [Related]
15. The metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [
Lu J; Bian Y; Zhang H; Tang D; Tian X; Zhou X; Xu Z; Xiong Y; Gu Z; Yu Z; Wang T; Ding J; Yu Q; Ding J
Xenobiotica; 2022 Jan; 52(1):38-45. PubMed ID: 34743655
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, Mass Balance, and Metabolism of the Novel Urate Transporter 1 Inhibitor [
Zheng Y; Zhang H; Liu M; Li G; Ma S; Zhang Z; Lin H; Zhan Y; Chen Z; Zhong D; Miao L; Diao X
Drug Metab Dispos; 2022 Jun; 50(6):798-808. PubMed ID: 34862252
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, mass balance, and metabolism of [
Ma S; Wang X; Yan S; Miao L; Wan X; Ding D; Yu D; Diao X; Wang X; Zhang H
Cancer Chemother Pharmacol; 2024 Mar; ():. PubMed ID: 38507062
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
19. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study.
Tiseo PJ; Perdomo CA; Friedhoff LT
Br J Clin Pharmacol; 1998 Nov; 46 Suppl 1(Suppl 1):19-24. PubMed ID: 9839761
[TBL] [Abstract][Full Text] [Related]
20. Metabolic disposition of [
Wang L; Guo L; Wang Y; Guo R; Xu Z; Gao Z; Xie L; Chen J; Chen Y; Liu Y; Zhang H; Bao L; Xu W; Zhu M; Shao F; Shu Y
Br J Clin Pharmacol; 2021 Mar; 87(3):1475-1485. PubMed ID: 32959915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
